IGF1 and congenital disorder of glycosylation: In particular, such a protocol could be instrumental for mechanistic studies understanding the specific role of IGF‐1 isoforms in cellular processes and signaling pathways, exploring the role of IGF‐1 in cancer biology, where differential expression or modification of IGF‐1 isoforms could contribute to tumorigenesis or cancer progression, and using IGF‐1 and proIGF‐1 as a biomarker in diseases like congenital disorders of glycosylation (CDG), where aberrant proIGF‐1Ea glycosylation has been observed.